Skip to content

Oncocyte

3 viewers · 30d

Total raised

$21.7M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $21.7M
ROUNDS
1
INVESTORS
12
FOUNDED
N/A
HQ
Irvine, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Oncocyte Corporation is a leading molecular diagnostics company committed to enhancing patient outcomes through advanced diagnostic testing solutions tailored for oncology and transplant care. By focusing on delivering actionable insights, Oncocyte empowers healthcare professionals to make informed medical decisions critical to patient treatment pathways.

What sets it apart

The company's unique commitment to merging cutting-edge technology with a patient-centric approach allows it to create personalized diagnostic solutions that directly address critical decision-making challenges in healthcare.

Funding history

1 round
Equity+2Feb 10, 2025
Form D
+$21.7M$21.7M total

Latest SEC filings

via EDGAR · CIK 0001642380
Form D · Feb 10, 2025View on EDGAR

Products

1 tracked

Molecular Diagnostic Tests

Diagnostic Testing

Oncocyte develops a comprehensive range of molecular diagnostic tests that enable healthcare providers to obtain vital patient information necessary for informed treatment decisions. These tests are strategically designed to be integrated seamlessly at key intervals throughout the treatment continuum.

  • Actionable diagnostic information
  • Focus on personalized insights
  • Application across oncology and transplant medicine
  • Integration into clinical workflows

Links

WebsiteSEC EDGAR filings